OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
Opko Health, Inc. (OPK)
Last opko health, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.opko.com
Company Research
Source: GlobeNewswire
— Results demonstrated potential to reduce current dosing frequency from once-daily to a single weekly injection — MIAMI and NEW YORK, Oct. 21, 2019 (GLOBE NEWSWIRE) -- OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced today that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with growth hormone deficiency (GHD) met its primary endpoint of non-inferiority to daily GENOTROPIN® (somatropin) for injection, as measured by annual height velocity at 12 months. Top-line results from the study demonstrated that treatment with somatrogon dosed once-weekly in pre-pubertal children with GHD was non-inferior to somatropin dosed once-daily with respect to height velocity at 12 months of treatment (the primary endpoint); the least square mean was higher in the somatrogon group (10.12 cm/year) than in the somatropin group (9.78 cm/year); the treatment difference (somatrogon – somatropin) in height velocity (cm/year) was 0.33 with
Show less
Read more
Impact Snapshot
Event Time:
OPK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPK alerts
High impacting Opko Health, Inc. news events
Weekly update
A roundup of the hottest topics
OPK
News
- GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024GlobeNewswire
- GeneDx CEO on q3 earnings beat, genetic testing and pediatric health [CNBC]CNBC
- GeneDx climbs after profitability milestone in Q3 [Seeking Alpha]Seeking Alpha
- GeneDx climbs after profitability milestone in Q3 [Seeking Alpha]Seeking Alpha
OPK
Earnings
- 8/7/24 - Beat
OPK
Sec Filings
- 11/4/24 - Form SC
- 9/27/24 - Form 4
- 9/27/24 - Form 4/A
- OPK's page on the SEC website